PIK3CA and cancer: In other forms of cancer, isoform-selective inhibition of PI3K has been shown to be an effective therapeutic strategy, and several isoform-selective inhibitors have been approved by the FDA for use in patients with chronic lymphocytic leukemia, lymphoma, or breast cancer [25].